Biolojic Design

Human Antibody Therapeutics

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in November 2010 by Yanay Ofran, Prof. and Avi Molcho, Biolojic Design operates with 51–200 employees. The company has secured $3.95M in total capital across 3 funding rounds from 4 investors. In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, potentially valued at up to 346 million euros.

Business overview

Biolojic Design is a biopharmaceutical company focused on developing human antibody-based therapeutics for cancer and other diseases. The company utilizes proprietary algorithms and computational tools to re-engineer antibodies, enabling them to bind new epitopes with high affinity. This re-epitoping technology allows for the creation of functional antibodies for challenging targets. Biolojic Design operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Digital Healthcare, serving the pharmaceutical and biotechnology industries.

Strategic signal

In June 2024, Biolojic Design entered a drug discovery collaboration with Merck, a deal potentially worth up to 346 million euros. This partnership validates Biolojic Design's computational and biochemical tools for antibody discovery and development, signaling strong commercial interest and potential for its re-epitoping technology in the pharmaceutical industry.

Company Intelligence Q&A

What was a significant recent commercial partnership for Biolojic Design?
In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, which could be valued at up to 346 million euros.
When did Biolojic Design appoint a new Chief Scientific Officer?
Biolojic Design appointed Ronald Herbst, Ph.D., as Chief Scientific Officer in September 2022.
What was the nature of the collaboration between Biolojic Design and Lilly?
In March 2021, Lilly and Biolojic Design announced a research collaboration to discover and develop antibody therapies for diabetes.
Which company launched Aulos Bioscience with Biolojic Design?
In January 2021, ATP and Biolojic Design launched Aulos Bioscience to develop an IL-2 antibody approach for fighting cancer.
What was a key development regarding Biolojic Design's computationally designed antibodies in 2022?
In April 2022, the first-ever computationally designed antibody created by Biolojic Design entered human clinical trials in cancer patients.

External links